Drug Profile

GB 262

Alternative Names: GB-262; PD-L1×CD55 bi-specific antibody - Genor Biopharma

Latest Information Update: 03 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genor Biopharma
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD55 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Mar 2025 Preclinical development is ongoing China (Genor Biopharma pipeline, March 2025)
28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
10 Apr 2021 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com